The Pacific Biosciences (PACB) assets in Illumina's (ILMN) broader distribution network will be additive to the commercial roll out of the 8M chip, Piper Jaffray analyst William Quirk tells investors in a research note titled "PacBio Deal Story More Than A Short Read." Further, he believes that if Illumina can manage the deal with a fraction of the Solexa efficiency, "it could be a home run." Strategically, he thinks the acquisition "makes a lot of sense combining a good product with a great execution team." Quirk keeps an Overweight rating on Illumina with a $384 price target.